bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the addition of Anterior Nasal Swab (ANS) as a validated specimen type for this panel, specifically for use with the respiratory test menu. By swabbing only the anterior part of the nasal cavity, ANS provides significantly more comfort for the patient.

On May 26, 2022, the team of Xiamen University, Hong Kong University, Wantai Biopharm and China National Institute for Food and Drug Control published online research results.

Genetic testing of saliva samples identifies the SARS-CoV-2 virus more quickly than testing of nasal swabs. The research is published March 21 in Microbiology Spectrum, a journal of the American Society for Microbiology.

Exponent announces that it has reached an agreement to sell BBI Group (“BBI”), a leading supplier of products and services to the global diagnostics and life sciences industries, to Novo Holdings A/S, a leading global life sciences investor, for an enterprise value of over ￡400 million.